Nama's AI scorecard currently rates Arcutis Biotherapeutics Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ARQT's P/E ratio?

Arcutis Biotherapeutics trades at a trailing price-to-earnings ratio of 121.7.

When does ARQT report earnings?

Arcutis Biotherapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.23.

What is the ARQT price target?

The median analyst price target from 8 analysts is $38.50, with a range of $34.00 – $48.00.

Is ARQT Shariah compliant?

Nama's AAOIFI-style screen reads Arcutis Biotherapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Arcutis Biotherapeutics (ARQT)

Healthcare · Biotechnology · NASDAQ

Arcutis Biotherapeutics (ARQT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.23B, a trailing price-to-earnings ratio of 121.7 and a free-cash-flow yield of -0.5%. Over the most recent reported fiscal year, revenue grew 91.3%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -3.7% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-26.6%

How far the last close sits under the highest price of the past five years.

Market cap	$3.23B
Trailing P/E	121.7
Price / book	14.5
Price / sales	6.9
FCF yield	-0.5%
Dividend yield	—
Gross margin	91.1%
Operating margin	7.4%
Net margin	6.2%
Revenue growth (YoY)	+91.3%
Revenue growth (3-yr annual)	+367.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ARQT earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.23). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.06	$0.17	-64.7%	$143.92M
Q2 2026	Aug 5, 2026	$0.11	$0.05	+120.0%	$129.86M
Q1 2026	May 6, 2026	-$0.09	-$0.06	-50.0%	$105.40M
Q4 2025	Feb 25, 2026	$0.13	$0.09	+44.4%	$129.50M

ARQT analyst price target

Median target $38.50 from 8 analysts, ranging $34.00 – $48.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ARQT data on Nama Insights →

Recent Congressional trades

Arcutis Biotherapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Jan 12, 2026
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023

ARQT FAQ

Is ARQT a buy?: Nama's AI scorecard currently rates Arcutis Biotherapeutics Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ARQT's P/E ratio?: Arcutis Biotherapeutics trades at a trailing price-to-earnings ratio of 121.7.
When does ARQT report earnings?: Arcutis Biotherapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.23.
What is the ARQT price target?: The median analyst price target from 8 analysts is $38.50, with a range of $34.00 – $48.00.
Is ARQT Shariah compliant?: Nama's AAOIFI-style screen reads Arcutis Biotherapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.